Efficacy, Tolerability, and Safety of Glucagon‐Like Peptide 1 Receptor Agonists (GLP1‐RA) in Kidney Transplant Recipients With Diabetes

Documenti analoghi

• Utilization and Outcomes of Glucagon‐Like Peptide‐1 Receptor Agonists in Posttransplant Diabetes Mellitus in Kidney Transplant Recipients
  di: Garyn Metoyer, et al.
  Pubblicazione: (2025)
• Impact of GLP‐1 and GLP‐1/GIP Receptor Agonist Weight Loss Post‐Lung Transplant on Lung Allograft Function
  di: Spenser E. January, et al.
  Pubblicazione: (2025)
• Cardio‐Renal‐Metabolic Outcomes Associated With the Use of GLP‐1 Receptor Agonists After Heart Transplantation
  di: Elena M. Donald, et al.
  Pubblicazione: (2024)
• Efficacy and Safety of Perioperative Angiotensin II Versus Phenylephrine as a First‐Line Continuous Infusion Vasopressor in Kidney Transplant Recipients
  di: Lyra P. Beltran, et al.
  Pubblicazione: (2024)
• Food Insecurity in Pediatric Kidney Transplant Recipients
  di: Priya S. Verghese, et al.
  Pubblicazione: (2025)